<DOC>
	<DOCNO>NCT02973204</DOCNO>
	<brief_summary>Background Treatment control cancer associate high cost , patient form side effect discomfort investigation , society form expensive drug study . Circulating tumor cell ( CTC ) receive great attention cancer biomarker try estimate future course patient breast cancer , colon cancer prostate cancer . CTC believe crucial step cancer spread bloodstream give rise metastasis . Detection circulate tumor DNA ( ctDNA ) specifically add specificity analysis CTC . The investigator would like molecular biological method predict patient require special monitor individualized therapy explore test clinical decision support . Purpose method In blood sample patient neuro-endocrine tumor ( NET ) hepatocellular carcinoma ( HCC ) , investigator cell separation , flow cytometry DNA sequence digital polymerase chain reaction ( PCR ) : 1 . Identify isolate CTC investigate tumor-specific mutation . 2 . Quantify ctDNA analyze specific mutation , past find frequent NET HCC . 3 . Compare findings mutation CTC ctDNA mutation tissue biopsy . The result compare clinical data disease course , include effect treatment survival . Subjects 40 Patients small intestinal/unknown primary NET treatment somatostatin analogues 30 patient pancreatic NET treatment Everolimus 30 patient presume radically treat HCC 30 patient HCC treatment Sorafenib A blood sample take prior start treatment , 1 month start treatment thereafter every 3.-6. month two year . Perspectives In several cancer type molecular diagnostics significant influence treatment control strategy . The goal future able take advantage so-called `` liquid biopsy '' clinical decision support . The study bring new knowledge grow field research .</brief_summary>
	<brief_title>Circulating Tumor Cells Tumor DNA HCC NET</brief_title>
	<detailed_description />
	<mesh_term>Neuroendocrine Tumors</mesh_term>
	<mesh_term>Carcinoid Tumor</mesh_term>
	<mesh_term>Neoplastic Cells , Circulating</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Lanreotide</mesh_term>
	<mesh_term>Angiopeptin</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Octreotide</mesh_term>
	<criteria>one mention disease plan surgery , RFA , Somatostatin Analogue , Sorafenib Everolimus treatment sign informed consent age 18 , concomitant invasive cancer ( skin cancer ) plan emigration Denmark .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>tumor DNA</keyword>
	<keyword>circulate tumor cell</keyword>
	<keyword>biopsy</keyword>
</DOC>